- Home
- CGEN vs TARA Comparison
CGEN vs TARA Comparison
Compare CGEN & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEN | TARA |
|---|---|---|
| Founded | 1993 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4M | 269.8M |
| IPO Year | 2001 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CGEN | TARA |
|---|---|---|
| Price | $2.26 | $4.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.00 | ★ $24.40 |
| AVG Volume (30 Days) | 513.4K | ★ 766.5K |
| Earning Date | 05-18-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $2.77 |
| 52 Week High | $3.24 | $7.82 |
Technical Indicators
Market Signals| Indicator | CGEN | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 34.51 |
| Support Level | $1.46 | $4.21 |
| Resistance Level | $2.35 | $4.59 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 3.64 | 4.29 |
Price Performance
Historical ComparisonAbout CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.